ReviewStem cell reviews and reports2009
The molecular mechanism of induced pluripotency: a two-stage switch.
Review in Stem cell reviews and reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Sgf29 regulates pluripotency by maintaining chromatin accessibility and promoting the expression of core transcription factors.Science China. Life sciences · 2026Article
- Feeder cell-dependent primary culture of single blastula-derived embryonic cell lines from marine medaka (Oryzias dancena).In vitro cellular & developmental biology. Animal · 2022Article
- Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.Pharmaceutical research · 2021Review
- SOX Transcription Factors as Important Regulators of Neuronal and Glial Differentiation During Nervous System Development and Adult Neurogenesis.Frontiers in molecular neuroscience · 2021Review
- Human iPSC banking: barriers and opportunities.Journal of biomedical science · 2019Review
- Adult Neural Stem Cells: Basic Research and Production Strategies for Neurorestorative Therapy.Stem cells international · 2018Review
- Article
- Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.Stem cell reviews and reports · 2017Review
- Cell culture density affects the stemness gene expression of adipose tissue-derived mesenchymal stem cells.Biomedical reports · 2017Article
- Epigenetic Modulation of Stem Cells in Neurodevelopment: The Role of Methylation and Acetylation.Frontiers in cellular neuroscience · 2017Review
- Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells.Scientific reports · 2015Article
- Primo-Vascular System as Presented by Bong Han Kim.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives.Stem cells and cloning : advances and applications · 2015Review
- Structure of the transcriptional network controlling white-opaque switching in Candida albicans.Molecular microbiology · 2013Article
- Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells.Stem cell reviews and reports · 2012Article
- Molecular mechanisms of induced pluripotency.Acta naturae · 2012Article
- Kinetic profiling of the c-Myc transcriptome and bioinformatic analysis of repressed gene promoters.Cell cycle (Georgetown, Tex.) · 2011Article
- Induced Pluripotent Stem Cells-A New Foundation in Medicine.Journal of experimental and clinical medicine · 2010Article
- Temporal anatomy of an epigenetic switch in cell programming: the white-opaque transition of C. albicans.Molecular microbiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pluripotent stem cells are basic cells with an indefinite self-renewal capacity and the potential to generate all the cell types of the three germinal layers. So far, the major source for pluripotent stem cells is the inner cell mass of the blastocysts: embryonic stem (ES) cells. Potential clinical application of ES cells is faced with many practical and ethical concerns. So, a major breakthrough was achieved in 2006, when it was shown that pluripotent stem cells could be obtained by transducing mouse embryonic and adult fibroblasts with a limited set of defined transcription factors. These reprogrammed cells, named induced pluripotent stem (iPS) cells, resembled ES cells in many of their characteristics. Since this initial study, iPS cell research has taken an incredible flight, and to date iPS cells have been generated from cells from several species using different sets of reprogramming factors. Given the potential to generate patient-specific cell populations without the need for human embryonic cells, iPS cell technology has been received with great excitement by research and medical communities. However, many questions regarding the actual molecular process of induced reprogramming remain unanswered and need to be addressed before iPS cells can go to the clinic. In this review, we start by summarizing recent advances in iPS cell research and inventory the hurdles that still need to be taken before safe clinical application. Our major aim, however, is to review the available data on the molecular processes underlying pluripotency reprogramming and present a two-stage switch model.
Indexed as
Identifiers
19551525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.